Related Experiment Video
Updated: Aug 6, 2026
09:27
New Tools to Expand Regulatory T Cells from HIV-1-infected Individuals
Published on: May 30, 2013
Is AIDS vaccine research at a turning point?
1Institut Cochin de Génétique Moléculaire, INSERM IFR 18, CNRS FR 20, Paris, France. levy@cochin.inserm.fr
Journal of Human Virology
|June 13, 2000
Summary
New AIDS vaccine strategies focus on non-ENV vaccines to elicit cell-mediated and mucosal responses. Key questions regarding protection in monkeys and immune responses in humans must be answered to advance to phase III trials.
Area of Science:
- Immunology
- Vaccinology
- Virology
Background:
- Initial anti-human immunodeficiency virus (HIV) envelope (ENV) vaccines have not yielded successful protection.
- Alternative vaccine strategies are needed to overcome limitations of previous approaches.
Purpose of the Study:
- To evaluate the potential of non-ENV vaccines for inducing cell-mediated and mucosal immune responses against HIV.
- To identify critical questions that need to be addressed to determine the efficacy of novel AIDS vaccine candidates.
Main Methods:
- Focus on non-ENV vaccine candidates.
- Assessment of cell-mediated immunity.
- Evaluation of mucosal immunity.
- Analysis of protection in non-human primate models.
Main Results:
- Non-ENV vaccines show promise for inducing cell-mediated and mucosal responses.
- Specific questions regarding reproducibility of protection in monkeys and immune responses in humans are critical.
Conclusions:
- Further research is required to answer key questions about the efficacy and safety of non-ENV vaccines.
- An accelerated international research effort could yield answers within 3-4 years, informing decisions on phase III trials.
Related Concept Videos
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
01:30Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...